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Acute pancreatitis (AP) is a common disease for which are attributable over 4000 hospitalization periods per 
year in Finland. Clinical symptoms include abdominal pain, nausea, vomiting, tachycardia, and takypnoe. 
The disease is most often associated with alcohol consumption, though biliary disease-induced AP is also 
common. Mild disease resolves spontaneously in a few days. Severe forms of the disease can lead to local 
complications, necrosis, and abscesses in and around the pancreas. Systemic inflammation in severe AP is 
associated with distant organ failures. Respiratory failure is the most common form of organ failure. Multiple 
organ failures carry high risk for lethal outcome. The severity of the developing AP has been an enigma for 
physicians for decades and has produced a considerable amount of scientific research. The factors that have 
been identified as associating with severe AP are age, co-morbid conditions and obesity.  
 
The aim of this study is to identify genetically determined prognostic factors involved in the clinical features 
of AP. The study employs a candidate-gene approach, and the genes are involved in trysinogen activation in 
the initiation phase of the disease, as well as in the systemic inflammation as the disease proceeds. The last 
study examines adipokines, fat-derived hormones characterized with the capacity to modify inflammation. 
 
SPINK 1 is a gene coding trypsin activation inhibitor. Mutations in sites N34S and P55N occur in patients 
with idiopathic and hereditary pancreatitis. These mutations were determined by minisequencing methods in 
371 AP patients and in 459 controls. The mutation N34S was more common in AP patients (7.8%) than in 
controls (2.6%). This suggests that SPINK 1 gene mutation N34S is a risk factor for AP.  
 
The inflammatory gene polymorphisms of TNF, HSPA1B, CD14 and IL-10 have been suggested to be 
involved in risk for alcoholic AP or in AP disease severity. In the study material of 397 AP patients and 310 
controls the genotypes were determined by MALDI-TOF-assisted methods. No differences could be 
identified between the different study groups.  
 
Hemostatic chances are closely associated with inflammation, suggesting that genetic changes favoring 
coagulation might be those factors associated with a more severe inflammatory response. Prothrombotic 
polymorphisms of coagulation Factor V gene (Leiden mutation) and plasminogen activator inhibitor-1 
(4G/5G promoter polymorphism) gene were determined in 397 AP patients. In our study population, the 
allele frequency for the Factor V Leiden mutation and the plasminogen activator inhibitor-1 4G allele was 
comparable to that of the general population.  
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In the fourth study, in 12 matched pairs of patients with severe and mild AP, levels of adipokines, 
adiponectin, and leptin were evaluated on admission and during the first week of hospitalization. During the 
course of AP, plasma levels of adiponectin were constant. Plasma adipokine levels did not differ between 
patients with mild and severe AP. In patients with mild AP leptin plasma levels decreased.  These results 
suggest that in AP, adipokine plasma levels are not factors predisposing to organ failures. 
 
This study identified the SPINK 1 mutation N34S to be a risk factor for AP in the general population. The 
inflammatory gene polymorphisms studied seem to play no role in alcohol-induced AP or in determining AP 
severity. The hemostatic polymorphisms studied showed no association with severe AP. Adipokines, 
adiponectin, and leptin seem to have no influence on systemic inflammation in clinical AP. As AP is a 
multifactorial disease, and extensive genetic heterogeneity is likely, further identification of genetic factors 
in the disease requires larger future studies with more advanced genetic study models. Further identification 
of the patient characteristics associated with organ failures offers another direction of the study to achieve 
more detailed understanding of the severe form of AP. 
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1  INTRODUCTION 
 
Patients with acute pancreatitis (AP) present with abdominal pain, nausea, and vomiting. Upper abdominal 
tenderness is frequently detected in clinical examination, and the pain often radiates to the back. In mild AP, 
uneventful recovery usually ensues in a few days following hospital admission. The clinical presentation of 
severe AP is severe abdominal pain, takypnea, tachycardia, oliguria, and shock, signs of Cullen and Gray 
Turner,1 and death. 
 
The most common etiologic factors for AP are alcohol or biliary stones. Incidence of AP in Finland is 
 80/100 000 per year, and familial pancreatitis is rare. No specific treatment exists. Treatment is symptomatic 
and includes pain relief and intravenous crystalloids in mild cases. As the disease turns into a severe form, 
patients receive prophylactic antibiotics. In severe AP, in addition to local complications in the pancreas,  
distant organ failures (OF) supervene. These patients receive treatment in intensive care units and need 
assistance regarding many organ functions.  
 
Genetic research in the field of AP has received no focus before this century. When studying complex 
genetic traits, precise definitions of phenotypes (trait components) are the starting points of the study. In a 
population of patients with AP, homogenous subgroups are identified based on clinical criteria. Differing 
etiologic factors and degree of disease severity, as well as complications of the disease categorize the 
patients.  
 
The severity of developing disease has been an enigma for physicians for decades and has produced a 
considerable amount of scientific research. The pathognomic processes involved in the progression of the 
disease are widely characterized. These involve inappropriate trypsin activation in the pancreas and 
activation of cellular and humoral inflammatory cascades. Systemic inflammation in AP includes production 
of cytokines, as well as disturbances in the coagulation system. The growing knowledge and detailed 
functional characterization of single nucleotide polymorphism has promoted genetic study of all the complex 
traits. Genotyping techniques are developing, and feasible genotyping techniques are now available. 
 
Finns have a common genetic background, and in that sense Finland offers an attractive field for a genetic 
study. Alcohol-induced AP is extraordinarily common in Finland compared to rates in other countries, 
meaning that some special genetic features may be responsible for the high Finnish incidence. 
 
This study applies the candidate-gene approach in series of 700 AP patients and controls. The aim is to 
identify genetic features that are prognostic factors associated with clinical aspects of AP. 
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2 REVIEW OF THE LITERATURE 
 
2.1 Clinical Aspects of Pancreatitis 
 
Pancreatitis is an inflammation of the pancreas, and the acute variety occurs suddenly, lasts for a short period 
of time, and usually resolves. Repeated episodes of AP may lead to chronic pancreatitis (CP), but the chronic 
form may also be triggered by only one acute attack, especially if the pancreatic ducts are damaged. CP 
results in a slow destruction of the pancreas. In CP, the patient has symptoms of pancreatic exocrine and 
endocrine dysfunction and continuous pain, and occasionally bursts of pancreatic inflammation resembling 
the clinical picture of AP. 
 
Epidemiology of acute pancreatitis 
 
The incidence of AP has risen during the past few decades in many countries.2, 3, 4 This rise is associated with 
increased alcohol consumption and possibly with a rising prevalence of obesity and accompanying gallstone 
disease.5, 6, 7 The incidence in Finland is extremely high and was estimated to be 73 cases/100 000 
inhabitants per year.8 In contrast, in Norway the incidence is 30 cases/100 000. 9 In Sweden, a novel decline 
in alcohol-induced AP has been detectable; however, at the same time, biliary AP has become more 
common, resulting in a rise in total AP incidence.10  
 
A factor influencing AP incidence is ethnicity. The hospitalization rate for AP in the United States is higher 
in blacks than in whites.4, 11 The alcoholic etiology of AP is extremely common in Finland, up to 80% of 
cases.12  
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 Mild and severe acute pancreatitis 
 
Clinical diagnosis of AP is based on clinical evaluation and detection of elevated amylase or lipase activity 
in serum, plasma or urine, but normal amylase activity does not rule out an AP diagnosis.17 In cases with 
normal amylase levels, computed tomography (CT) can verify the diagnosis.18 Differential diagnosis of AP 
includes peptic ulcer disease, abdominal perforations and peritonitis, appendicitis, acute myocardial 
infarction, and other conditions. 
 
In the majority of patients, the course of AP is mild and self limiting; abdominal pain is relieved in a few 
days by general supportive care, and local and systemic complications are rare. Early prediction of the 
severity of an acute attack has important implications for management and intervention. Severe AP is 
characterized by local complications in the pancreas and distant OF compromising survival. The precise 
definition between mild and severe AP should be unambiguous and has been the topic of continuous debate 
for pancreatologists.  
 
Ranson and colleagues provided the first prognostic criteria for AP in 1974.19 These criteria consist of eleven 
signs evaluated within 48 hours of admission. Identification of three or more positive signs is prognostic for 
severe AP. Sign numbers higher than six are associated with mortality of more than 50% and systemic 
Country, yearreference 
Incidence of AP  
(cases /100 000) 
Proportion of alcohol-induced 
AP (%) 
Germany 1995 13 20  32 
Norway 1995 9 20  19  
Ireland 2004 14 23  23 
Iceland 1999 15 32 32 
Sweden 1999 16 35  25  
 USA, California 2001 11 44  20 
Finland 1989 7 73   60 
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complications. The Ranson factors also correlate with pancreatic necrosis.20 Later, Imrie in Glasgow 
modified the scoring system by simplifying it to eight points.21  
 
The Atlanta severity classification was established in the International Symposium on AP in Atlanta, 
Georgia, in 1992. It is a clinically based classification system for AP.22 According to this classification, 
severe AP is associated with OF alone or with local complications such as necrosis, abscesses or 
pseudocysts. Furthermore, accumulation of three or more Ranson criteria or eight or more Acute Physiology 
and Chronic Health Evaluation II (APACHE II) points 23 characterizes severe AP. The Atlanta classification 
is retrospective in nature and was developed for comparison of patient series. While the Atlanta classification 
may be ambiguous, its revision has been proposed.24, 25 
 
APACHE II, Multiple Organ Dysfunction Score,26 and Sequential Organ Failure Assessment 27 scores are 
examples of scoring in assessing OFs. OF in AP correlate closely with mortality,12, 28 and thus OF scores are 
informative also in profiling AP patients. 
 
The gold standard for laboratory assessment of severity of AP is C-reactive protein (CRP) concentration.29 A 
value for CRP concentration > 150 mg/l has a specificity of 90% for severe AP on admission to hospital.30 
Contrast-enhanced CT is also a widely used means to classify AP severity.31, 32 
 
Alcohol-induced acute pancreatitis 
 
Only a minority of alcoholics develop pancreatitis, suggesting individual susceptibility to 
the disease.33, 34, 35, 36 This implies some individual risk factors or alternatively, protective factors. It has also 
been noted that the incidence of alcoholic pancreatitis is proportional to amount of alcohol consumption, 
suggesting the presence of dose-related effects of alcohol on the pancreas.37,  38 
 
It is estimated that about 10 to 20% of individuals who consume large amounts of alcohol eventually develop 
pancreatitis. 39  It probably makes no difference whether the ethanol is consumed as wine, beer, or spirits, but 
the daily consumption in patients with pancreatitis averages 100-150 g/day.40 It has also been suggested that 
not the continuous drinking but the withdrawal period is crucial in triggering the first episode.41 Another 
postulate is that the amount of alcohol consumed during the week of the first attack of AP correlates with 
disease severity.42  
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The mechanisms by which alcohol triggers AP are not solidly defined.43 It is likely that multiple factors 
together predispose to the disease. 44 The effects of alcohol and its metabolites and its metabolic by-products 
(reactive oxygen species) 45 may lead both to increased content of digestive and of lysosomal enzymes, and 
also to increased potential for contact between digestive and lysosomal enzymes in the pancreatic acinar cell. 
One cause is increased organelle fragility mediated by compounds such as cholesteryl esters, fatty acid ethyl 
esters, and reactive oxygen species.46 These changes may facilitate premature intracellular activation of 
digestive enzymes and may predispose the gland to autodigestive injury and necroinflammation, if an 
appropriate trigger factor is present. 
 
Among such trigger factors is smoking. Cigarette smoking alone may induce pancreatitis, or it may have an 
additive effect with alcohol. Different dietary components may interact and modify the effects of alcohol on 
the pancreas. The poor vitamin status of patients with alcoholic AP may be contributory.47 Ethnicity may be 
a contributory factor, for example afroamerican individuals may be at increased risk for alcohol-induced 
pancreatitis.48, 49 Furthermore, viral infections and bacterial endotoxin may also be triggering cofactors.50, 51, 52 
 
Treatment of acute pancreatitis 
 
No specific treatment exists. The usual treatment is to give intravenous fluids to prevent dehydration, plus 
sufficient pain control. Treatment of AP is mainly symptomatic and supportive. During the first days the 
patients are not given any food until the symptoms disappear. However, in cases with severe AP, enteral 
feeding is recommended and started with a nasojejunal catheter during the first few days. 53  Patients with 
severe AP receive intravenous fluids, prophylactic and target-specific antibiotics, and supportive care in an 
intensive care unit. Abdominal compartment syndrome, gut necrosis, and uncontrollable hemorrhage are 
reasons for surgical intervention in the early phase of the severe disease.54 After two weeks of severe AP, 
infected necrosis is the most common indication for surgery.55, 56 
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Prognosis of acute pancreatitis 
Mortality rates 
 
In recent reports, hospital mortality from severe AP was between 15 to 30%. 57, 58 The reduction in mortality 
from AP during the last two decades is attributed to early identification of severe AP and appropriate 
intensive care unit management.59 Many AP patients die within the first two weeks of onset.60, 61 Another 
peak in mortality occurs in the late phase, weeks after the onset of the disease, and is associated with 
infectious complications of pancreatic necrosis.62, 63 Approximately one-third of all deaths due to AP are 
outpatient fatalities, and these deaths are strongly associated with social isolation and alcohol abuse.64, 65 
 
Risk factors  
 
Systemic inflammatory syndrome (SIRS) that persists over 48 hours is associated in AP patients with 
multiple organ dysfunction and death.66 Persistent SIRS has been associated with a mortality of 25% 
compared to lower than 10% in those SIRS resolving in less than 48 hours.67 Advanced age, chronic 
comorbid conditions, and need for dialysis, mechanical ventilator support, and vasopressor support are 
prognostic factors for a fatal outcome.68, 69 
 
Obesity is a clear risk factor for AP. It is not only a risk factor for the development of local and systemic 
complications; it also leads to increased mortality.70, 71, 72 
 
Alcoholic pancreatitis is an etiologic factor associated with higher mortality rates73 and with more frequent 
development of pancreatic necrosis74, 75 than in other forms of AP. This finding is not consistent, however.76 




Detrimental effects on patient health due to AP include exocrine and endocrine pancreatic insufficiencies 
that correlate with amount of pancreatic necrosis.79 Approximately half the patients develop impaired 
glucose intolerance after severe AP.80 Insulin-dependent diabetes mellitus after severe AP is a more rare 
manifestation, presenting in approximately 10% of cases.81 Repeated episodes of alcoholic AP may lead to 
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CP. Up to 13% of severe AP patients surviving their initial hospitalization die within a few years. Among the 
survivors, long-term health-related quality of life is comparable to that of the normal population. 82 
 
 
2.2 Pathogenesis of Acute Pancreatitis 
 
The pancreas is located retroperitoneally in the upper abdomen, behind and below the stomach, and is 
connected to the intestinal tract by the pancreatic duct which opens into the duodenum. The pancreas can be 
divided into two separate units, one endocrine and one exocrine. The endocrine pancreas regulates energy 
metabolism by secretion of various hormones into the blood stream and is structurally located in distinct 
clusters of endocrine cells called the islets of Lagerhans. The blood supply of the endocrine pancreas is 
provided by one to five arterioles per islet.83 The islets of Lagerhans comprise 1% of the pancreatic mass, but 
receive up to 15% of the organ´s blood supply. The exocrine pancreas, the main part of the gland, secretes 
pancreatic juice into the intestinal tract. The pancreatic juice contains enzymes capable of digesting 




Pancreatic digestive enzymes are stored as inactivated precursors in pancreatic zymogen granules. Under 
normal conditions, their activation is strictly controlled to prevent autodigestion of the pancreas; activation 
occurs in the small bowel. In certain circumstances, however, excessive amounts of pancreatic trypsinogen 
are activated to trypsin (ectopic activation), activating other downstream zymogens, and leading to 
autodigestion of the pancreas. Triggers for the activation of trypsinogen to trypsin in the pancreas include 
excessive pancreatic exocrine stimulation, reflux of bile or duodenal fluid, disturbance of pancreatic duct 
flow, and inflammation. Altough enterokinase is the most efficient activator, other molecules activating 
trypsinogen include trypsin, lysosomal enzyme catepsin B, and neutrophilic enzymes. Activation of trypsin 
from trypsinogen can also occur without enzyme involvement (non-enzymatic autoactivation). Calcium 
inhibits degradation (autolysis) of activated trypsin, whereas bile acids promote trypsin autoactivation. 
 
SPINK1 (serine protease inhibitor, Kazal type 1), also called pancreatic secretory trypsin inhibitor or tumor-
associated trypsin inhibitor, is synthesized in acinar cells of the pancreas and is thought to inhibit up to 20% 
of the pancreatic trypsin activity by binding to its catalytic site. Pancreatitis can develop if pancreatic 
activation of trypsinogen is too high, or the trypsin-binding ability of SPINK 1 is too low. 84 85 86 
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Figure 1. The cascade of pathognomic events in the progress of severe AP. Trypsinogen is the precursor of trypsin, 
the most important digestive enzyme produced in the pancreatic acinar cell. The most important inhibitor of pancreatic 
trypsin activity is SPINK1. 
 
 
Autodigestion of the pancreas causes necrosis, apoptosis, and vascular damage in the pancreas, and various 
proteolytic and lipolytic enzymes are released and activated within the organ.87 The noxious potential of 
elastase, lipase, chymotrypsin, and phospholipase A2 exceeds that of trypsin in damaging acinar cells. 
 
Acc co-localization hypothesis, he early stages of AP, pancreas-derived digestive 
zymogens become co-localized with lysosomal hydrolases in acinar cell cytoplasmic vacuoles, and as a 
result of this co-localization, lysosomal hydrolases such as catepsin B activate trypsinogen.88 Furthermore, 
trypsin activates other digestive enzyme zymogens.  
 
Neutrophils are recruited from the general circulation to the site of damage. Reactive oxygen species 
generated by infiltrating neutrophils are considered important regulators in the pancreatitis pathogenesis. The 
inflammatory cells, macrophages, fibroblasts, T-cells, and endothelial cells, along with damaged acinar cells, 
are responsible for the release of inflammatory mediators into the systemic circulation.  
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Local injury in the pancreas may proceed to a systemic inflammatory response syndrome (SIRS). This 
syndrome is characterized by tacypnoe, tachycardia, high leukocyte count, and abnormal body temperature.89 
Persistent SIRS is associated in AP with multiple organ dysfunction syndrome and death and is an early 
indicator of AP severity. 
 
The mediators of systemic inflammation in the pancreatitis include a variation in cells and cytokines. 
-
wide variety of genes involved in the inflammation in AP.90 During severe AP, the pro- and anti-
inflammatory cytokine response occurs early and persists in the systemic circulation for several days.91 
Severe AP has many similarities to sepsis syndrome and septic shock. The hemodynamic features of 
cardiovascular instability, reduced ejection fraction, and decreased systemic vascular resistance in each of 
these conditions are indistinguishable. In addition, similarities in the cytokine and inflammatory mediator 
profiles are striking, suggesting that the hemodynamic abnormalities may result from the same pathogenic 
mechanisms. 
 
In addition to hyper-cytokinemia resulting from the inflammatory process in the pancreas and peripancreatic 
tissues, evidence exists that when AP is complicated by infection these cytokines are released by hyperactive 
macrophages.92 Cytokines activate neutrophils that have already infiltrated vital organs such as the lung, 
liver, and digestive organs. By excreting proteolytic enzymes, neutrophils injure the infiltrated vital organs, 
causing cellular damage and dysfunction of vital organs distant from the pancreas. 
 
Although septic complications of severe AP do arise, these are usually late features. In the early phase of a 
severe attack, sterile pancreatic necrosis occurs. Evidence suggests that the important cytokines in the 
development of complications and multiple OF in severe AP , interleukin-
1 (IL-1), interleukin-6 (IL-6) and interleukin-8.93, 94 In addition, endotoxin and other important inflammatory 
mediators including platelet activating factor and phospholipase A2 are implicated in the development of 
complications in both severe AP and sepsis.95 Furthermore, trypsin and activation of circulating trypsinogen 
in AP may contribute to development of distant organ injury.96  
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cinar cells from the pancreas and by activated peripheral blood monocytes. The 
systemic up-regulation -signaling molecules released from the 
pancreas that gain access to the general circulation. In AP, TNF  overproduction is pivotal in the induction 
of inflammatory genes, cell death, endothelial upregulation, and in the recruitment and activation of immune 
cells.97 TNF is rapidly cleared from the bloodstream, has been considered as a novel pharmacologic 
target for treatment. Although promising results have emerged from the laboratory, their use in clinical 
practice seems problematic.98, 99 
 
Interleukin-1 
IL-1 -1 is detectable within the pancreas early in the 
course of experimental AP.100 Upregulation of IL-1 occurs not only within the pancreas, but during the 
course of AP also in distant organs. In addition to high levels of IL-1in severe AP, levels of IL-1 receptor 
antagonist (RA) are also higher.101 Because negative feedback occurs between IL-1 and IL-1RA, IL-1 RA 
may attenuate AP severity.102, 103, 104 
 
Interleukin-6 
IL-6 is important in the induction of synthesis of acute-phase proteins and is a clearly defined marker of 
disease severity in AP.105, 106 Experimental models have shown that IL-6 has implications in the development 
of the disease.107 
 
Interleukin-10 
Early during the clinical AP, IL-10 plasma levels peak.108 In clinical settings, IL-10 plasma levels are quite 
useful in predicting severe AP and OF on admission to hospital.109, 110, 111, 112, 113 This cytokine ameliorates 
AP in experimental settings.114, 115, 116 Due to its anti-inflammatory properties, IL-10 has been suggested for 
use as a drug to ameliorate AP; however, clinical trials in humans have been unsuccessful.117  
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CD14 and endotoxin 
CD14, a membrane-associated protein expressed on the surface of cells, especially of macrophages, acts as a 
receptor for detection of bacterial lipopolysaccharide, i.e., endotoxin. Intestinal permeability to various 
compounds and endotoxin is higher among patients with severe AP than among those with mild AP.118 The 
presence of endotoxemia predicts poor outcome in AP.119  
 
Animal models have demonstrated that endotoxin potentiates lung injury,120 and the anti-CD14 antibody 
ameliorates severe AP and pancreatic injury.121 CD14-deficient mice develop biochemical manifestations of 
AP, but their histological changes are more subtle than in controls.122 Endotoxin has been suggested to act as 
a cofactor during alcohol-induced AP in pancreatic necrosis of cells. The pancreas exposed to alcohol is 
more sensitive to endotoxin-induced damage, due to its increased sensitivity to necrotic rather than apoptotic 
cell death.123 
 
Heat shock proteins 
Heat shock proteins (HSPs) are a group of proteins whose expression is increased when cells are exposed to 
elevated temperatures or other stress. HSPs, cytoprotective molecules that help to maintain the metabolic and 
structural integrity of cells, are designated according to molecular weight, for example, HSP70 refers to a 
family of heat shock proteins on the order of 70 kilodaltons in size. HSPs are upregulated in AP124, 125 and 




Related to systemic inflammation in AP are abnormalities in coagulation and fibrinolysis.131, 132 Consumptive 
coagulopathy is demonstrated by decreased platelet counts, decreased prothrombin values, and consumption 
of fibrinogen during the first days of severe attacks. 133 Severe hemostatic disorders in AP may range from 
scattered intravascular thrombosis to disseminated intravascular coagulation. 134, 135, 136  
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Plasminogen activator inhibitor-1  
Plasminogen activator inhibitor-1 (PAI-1) is an inhibitor of fibrinolysis, the physiological process that 
degrades blood clots. Non-survivors of AP have higher concentrations of PAI-1 and d-dimer and lower 
activity of protein-C than do survivors.137, 138 
 
 
2.3 Genetic Factors in Pancreatitis 
 
 Familial pancreatitis 
 
Families with numerous members suffering from repeated episodes of pancreatitis are called familial 
pancreatitis families. Repeated acute episodes lead to fibrosis and calcifications of the gland. Research in 
familial pancreatitis has been successful in identifying genetic determinants related to pancreatitits. These 
findings can be applied to candidate genes in AP.  
PRSS1 
 
Hereditary pancreatitis (HP) is a rare form of recurrent AP and CP. A HP family was first described in 
1952,139 and recently one Finnish family was described.140 The simple Mendelian model of inheritance of HP 
suggests that a single genetic defect is responsible for this disorder. With use of a genome-wide genetic 
linkage analysis, the gene was mapped to chromosome 7q35 in a large French family in 1996; 141 this finding 
was concurrently confirmed by two other groups. 142, 143 Subsequent candidate gene sequencing of the 7q35 
chromosome region revealed a strong association of the c.365G > A (p.R122 H) mutation of the PRSS1 gene 
encoding cationic trypsinogen with HP. Later, other mutations of this gene emerged in patients with 
hereditary or idiopathic CP. In vitro, these mutations lead to increased autocatalytic conversion of 
trypsinogen to active trypsin and thus probably cause premature intrapancreatic trypsinogen activation in 
vivo. The clinical presentation is highly variable, but most affected mutation carriers have a relatively mild 
disease;144 however, these patients carry a risk for pancreatic cancer.145 Mutations in PRSS1 are rare among 
patients with alcoholic CP and in patients with idiopathic CP.146 
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In 2000, Witt and colleagues first recognized the high incidence of mutations in the SPINK1 gene in children 
and adolescents with CP.147 In subsequent studies, the association between exonic SPINK1 mutations, 
especially the allele called N34S, and idiopathic148, 149 and familial CP has been confirmed throughout the 
world. Homozygote carriers of the SPINK1 N34S mutation are characterized by symptoms of CP in early 
childhood.150 In several of these studies, the gene has been sequenced, with several variants described.151 , 152 
Furthermore, rare, clearly disease-causing mutations resulting in a complete functional loss of the protein 
have emerged.153 
 
Some studies on alcoholic CP revealed a less vital limited contribution by the exonic SPINK mutations to the 
disease.154, 155 The prevalence of the N34S and P55S mutations was 6.3% among patients with chronic 
alcoholic pancreatitis in the United States156 and 2.4% in Korea.157 In a report from India, the N34S mutation 
was recognized in 26.8% of patients with alcoholic CP.158 The frequency of the N34S mutation in control 
populations has varied: 2.5% in Great-Britain, 2.8% in India, 1.6% in the United States and in Japan, and 0% 
in Brazil.159 In a Finnish CP, sample prevalence of the N34S mutation was 12%.160 
 
The SPINK1 gene is located on chromosome 5. The activity of the SPINK1 protein with the point mutation 
N34S is comparable to that of the wild-type protein; thus, the exact mechanism by which the N34S mutation 
is associated with pancreatitis remains unknown.161 Some speculate that haplotypes and intronic mutations 
associated with the N34S mutation are responsible for N34S being associated with decreased expression of 
SPINK1. Alternatively, increased degradation/inactivation by enzymes other than trypsin may be involved. 
In SPINK1 knockout mice, the pancreas is absent. Because remnants of the pancreas appeared in some of the 




Cystic fibrosis gene (CFTR, cystic fibrosis transmembrane conductance regulator) mutations have been 
associated with CP. Cystic fibrosis, an autosomal recessive inherited disorder characterized by chronic 
obstructive pulmonary disease, also involves exocrine pancreatic insufficiency with maldigestion and 
increased sweat chloride concentration. Its incidence in the white population worldwide is about 1:2500. In 
Finland the disease is rare.163 Several studies have found CFTR mutations in up to 30% of patients with 
idiopathic CP. CFTR mutations are associated with CP especially in patients with two or more heterozygous 
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mutations or one mutation accompanied by mutations of PRSS1 and SPINK1164, 165 Penetrance of the 
identified pancreatitis-associated mutations is apparently incomplete. 166 
 
Complex trait of acute pancreatitis 
 
According to classical genetics, diseases are divided into Mendelian disorders and complex traits. While the 
former are attributed to single gene mutations with a simple inheritance, like familial pancreatitis, the latter 
are attributed to multiple genes, each playing a small and interactive role in susceptibility to the diseases. For 
complex traits, the contributions of most of the multiple etiologic factors are likely to be modest. In diseases, 
interaction with multiple genetic loci (locus, fixed position on a chromosome) and environmental factors is 
essential. Much heterogeneity exists, which means that different alleles (DNA coding that occupies a given 
locus) or loci cause disease in different groups. Incomplete penetrance is also a factor, meaning that not all 
susceptible individuals are affected.  
 
In the case of AP, we have insufficient means to assess the amount of genetic load and heritability. Twin 
studies are one way to assess the impact of genetic predisposition to a disease.167 In AP, however, such 
studies are unavailable. Furthermore, the hereditability of alcohol-induced AP is undefined. In alcoholic 
pancreatitis, the environmental effect is essential in triggering the disease. Clinicians repeatedly ask, 
however, why only a sub-set of alcoholics develop alcoholic AP and CP. The answer is still undiscovered
but may associate with factors related to complex inheritance of the disease. Variation in a trait may be due 
to genetic variability in one group and to environmental variation in another.  
 
The genetic factors involved in severe AP are likely to possess all the major features of complex traits. This 
includes additive effect of multiple minor components. The penetrance of each gene is influenced by gene-
to-gene interactions and by interactions between the gene and the environmental and acquired factors. It is 
likely that several acquired conditions that are thus far unrecognized act as cofactors. It is likely that the 
allele frequency of the variations involved is relatively low in population. This coincides with the fact that 
the homozygote, with the special polymorphism/mutation, may be severely affected as AP interferes. Family 
trees are the only possible way to identify these rare variants. Protective genetic factors may also be 
responsible.  
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Defining the trait components 
 
The classification of complex traits into well-defined categories, trait components, is the prerequisite for 
understanding the underlying pathogenetic mechanisms. Ideally, these trait components would be concordant 
with the genetic factors responsible for the phenotype. Poorly defined classification and phenotyping easily 
destroys all feasibility for a genetic study. In AP, this requires precise diagnosis and accurate classification of 
severity.  
 
AP diagnosis must be definite. Inappropriate diagnosis is most often attributed to an overlooked differential 
diagnosis of hyperamylasinemia. Amylase values are easily elevated in patients with perforated peptic ulcer 
disease, intestinal obstruction or infarction, and in ruptured ectopic pregnancy, and postoperatively. The 
specificity of a serum amylase in determining AP can be increased by use of a cutoff of more than two to 
three times the upper limit of normal.168 One of the frequent causes for hyperamylasinemia is renal 
insufficiency, which is associated with diminished excretion of amylase. Additionally, salivary gland lesions, 
various tumors (lung, esophagus, ovary, breast), pregnancy, burns, diabetic ketoacidosis, or drugs (morphine, 
codeine) may all cause hyperamylasinemia.  
 
Differentiation between cases of AP and CP demands precision from the clinician. Diagnosis of CP is based 
on pancreatic exocrine or endocrine insufficiency or typical radiological signs of strictures in the pancreatic 
duct or calcifications in the parenchyma of the gland. Seldom diagnosis is made on histology specimens. 
Diagnostic tests for CP are not used routinely in emergency departments. Thus, inclusion of cases that have 
already developed CP easily interferes with assessment of patients with AP. Exclusion of CP patients can be 
done most strictly by including only those experiencing their first episode of AP although few of these 
patients may have signs of CP in a thorough examination. 
 
In patients with AP, different etiologies deserve their own categories. The alcoholic etiology is often easily 
detected by taking a proper history.169 Degree of alcohol dependence can also be measured by validated 
questionnaires (The Alcohol Use Disorder Identification Test, AUDIT; The Short Alcohol Dependence Data, 
SADD). However, patients tend to overlook or lie about their use of alcohol, and it is obvious that some 
patients with a diagnosis of idiopathic AP suffer from alcohol-induced AP. Laboratory parameters (red blood 
cell mean corpuscular volume and disialotransferrin) are an additional aid for the physician in differentiating 
between alcohol and other etiologic factors. Biliary AP is associated with elevated liver values as well as 
dilatation in intra/extrahepatic bile ducts as signs of biliary stones in imaging studies. Idiopathic AP can be 
diagnosed in cases with no eligible etiologic diagnosis.170 This means exclusion of alcoholic and biliary 
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etiologies, and rarer, but obvious etiologies for AP: familial pancreatitis, drugs, hypertriglyceridemia or 
hypercalcemia.  
 
A definition of severe AP deserves some delineation for purposes of genetic studies. Widely used 
classifications like the Atlanta and Ranson serve as a sufficient basis regarding mild versus severe AP. The 
trait components in severe AP must, however, include identification of local and systemic complications 
separately. The systemic complications include the distant OFs occurring early during the disease (during the 
first week). Early OF may to be associated with more advanced local complications and a complicated 
clinical course. Early OF that is continuous is associated with mortality, and must be defined as a trait 
component as such. OF occurring later represent another phenomenon, and are closely associated with 
infectious complications locally and around the pancreas. Local complications with infection are associated 
with late mortality. Individual susceptibility to infectious complications in necrotic foci in and around the 
pancreas may in part be genetically determined. The late infectious complications are important, since these 
contribute to AP mortality.  
 
Candidate gene studies 
 
The scientific community has shown interest in genetic determinants of disease severity in AP since the early 
1990s.171 Table 2 presents the case-control studies including patients with AP. 172 
 
Genetic studies in chronic pancreatitis 
 
Idiopathic CP is the leading type of CP in children and in nonalcoholic adults. The risk for developing it is 
higher in individuals who have mutations of the CFTR and of SPINK1genes. In studies from the United 
States and France, risk for idiopathic CP is increased about 40-fold from having two abnormal copies of the 
CFTR gene, about 14-fold from having the N34S SPINK1 mutation, and about 500-fold by having both. 
When idiopathic CP patients have two abnormal copies of the CFTR gene, there is also evidence of reduced 
residual CFTR protein function in extrapancreatic tissues based on clinical findings and nasal ion transport 
responses.173 The human major histocompatibility complex (MHC) is a group of genes residing on 
chromosome 6 which code for the human leukocyte antigen system (HLA). This region was early recognized 
to have influence on inflammatory processes. Numerous investigations from the 1980s reported dissimilar 
associations between different HLA subtypes and CP.174, 175, 176, 177, 178, 179  
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A summary of genetic case-control studies in CP is in Table 3. 
 
2.4 Genetic Factors in Systemic Inflammation 
 
The markedly different responses of seemingly similar individuals to the same inflammatory or infectious 
agents has attracted notice. The death from infection of a biological parent is associated with a five-fold 
greater risk of death from infection in adoptees.180 For a seemingly adverse mutation to be preserved in the 
human genome, a survival advantage in another single disease,  is a prerequisite.181  
 
 Cytokine gene polymorphism 
 
Genes coding for cytokines are important candidate genes for determining the strength of a individual`s 
response to injury. In cells, genes consist of a long strand of DNA that contains a promoter which controls 
the activity of a gene and a coding sequence, which determines the gene products. Study of polymorphisms 
in the areas of gene promoters of cytokine genes has exploded during the past ten years. 182,183,184,185,186 
Associations may exist between specific polymorphisms and ischemic heart disease,187 sepsis and septic 
shock,188 surgical injury in aortic repair,189 and psoriaisis.190  
 
Hemostatic gene polymorphism 
 
The importance of hemostatic gene polymorphism for the clinical picture of an infectious disease was 
pointed out in 1999 by investigators of meningococcal disease.191 Patients carrying the PAI-1 4G/4G 
prothrombotic genotype had higher mortality. These results were repeated by another group some years 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The Leiden mutation of FV is a procoagulative mutation with a population prevalence of 3% to 5%. FV 
Leiden is a risk factor for deep venous thrombosis, but may be advantageous in severe infections. 231 
 
Genetic determinants of coagulation and fibrinolysis are candidate genes in sepsis 232 and in lung injury.233 
Study of the importance of these polymorphisms in coronary heart disease has been extensive, but their 




Obesity has a strong hereditary component.235 Adipokines are fat-derived hormones and responsible for 
metabolic effects of obesity such as low-grade systemic inflammation. The most well-known adipokines are 
adiponectin, identified in 1996 and leptin, identified in 1994. 
 
In obesity adiponectin is downregulated. Several clinical studies demonstrate the inverse relationship 
between plasma adiponectin levels and several inflammatory markers including CRP.236 Adiponectin 
attenuates inflammatory responses to multiple stimuli by modulating signaling pathways in a variety of cell 
types. The plasma level of adiponectin is, in part, genetically determined.237, 238 The latest studies in 
homozygotic twins do support this.239 The APM1 gene, the gene encoding adiponectin, has been suggested to 
be an important determinant of adiponectin levels.240 , 241, 242, 243, 244  
 
In obesity leptin is upregulated. In contrast to adiponectin, leptin has proinflammatory properties and may 
enhance systemic inflammatory reactions.245, 246, 247 It is encoded by the Ob gene. The receptors for leptin are 
more tightly genetically determined than are those for plasma levels of leptin.248 Leptin levels are, however, 





3 PRESENT INVESTIGATION 
 
3.1  Aims of the Study 
 
The purpose of the present study was to identify genetically determined prognostic factors in AP. 
 
The specific aims of the study were to: 
 
1. Evaluate the relevance of SPINK1 gene mutations N34S and P55S in AP patients. 
 
2. Discover whether polymorphisms of the inflammatory genes CD14, TNF, IL-10, and 
HSPA1B are associated with severe AP and alcohol-induced AP. 
 
3. Discover any association between the procoagulative hemostatic gene polymorphisms 
PAI-1 4G/5G and FV Leiden and severe AP. 
 
4. Define whether adipokines, with their capacity to modify systemic inflammation, are 





3.2 Patients and Methods 
 
Patients with acute pancreatitis 
 
Study I: 324 patients were included between September 1998 and April 2003 at the emergency unit of the 
Helsinki University Central Hospital. Additionally, a retrospectively recruited group had severe AP during 
the 1990s, and this group comprised 47 patients. These patients were contacted by letter invitation and 
volunteered for blood sampling.  
 
Studies II & III: This prospectively collected group comprised 349 AP patients admitted to the Helsinki 
University Central Hospital Emergency Unit during the years 1998 to 2003. A retrospective group of 48 
patients with severe AP during the 1990s was available from Study I.  
 
Study IV: The study population comprised 410 patients admitted to the Helsinki Central Hospital from April 
1999 to January 2004. Because adipokine levels are associated with gender and body mass index (BMI), a 
matched case-control design was used. Matching included gender, age (±10years), BMI (±3kg/m2) and 
etiology of AP. A total of 12 pairs could be identified among the 410 patients with AP.  
 
The study protocols were approved by the local institutional ethics committee. The patients gave their 
informed consent for participation in the study. 
 
 
























II 397 284 (72%) 152 (38%) 55 (14%) 214 (54%) 
III 397 284 (72%) 152 (38%) 55 (14%) 214 (54%) 
IV 24 16 (67 %) 12 (50%) 8 (33%) 14 (59%) 






Study I: 459 blood donors served as controls (The Finnish Red Cross, Helsinki, Finland).  
 
Studies II & III: A total of 310 individuals served as controls; 218 were from the WHO/ISBRA Multicenter, 
Multinational Study on the Trait and State Markers of Alcohol Consumption and Alcoholism250 and 
comprised Finnish men with detailed data of their alcohol consumption. Of these 218 men, 70 consumed 
alcohol amounting to more than 40 g/day; these formed a subgroup of controls denoted as heavy drinkers. Of 
the 218 controls, 59 were non-drinkers, and 89 consumed <40 mg alcohol per day. Additionally, 92 blood 
donors (The Finnish Red Cross, Helsinki, Finland) provided blood samples as controls. All the controls and 
the cases were Caucasian and originated from the comparable geographic area of Finland Uusimaa. 
 
Study IV: Patients with mild AP served as matched controls for patients with severe AP.  
 
Definitions of phenotypes 
 
Diagnosis: AP was diagnosed if the patient had a clinical presentation consistent with AP and a plasma 
amylase activity greater than three times the upper reference limit, or confirmation of AP by CT in patients 
with normal or marginally elevated amylase concentrations. Abdominal pain, increased tenderness, rebound, 
distension, vomiting, fever, tachycardia, bowel paralysis, Grey Turner´s sign or Cullen´s sign were 
considered clinical signs of AP. 
 
Alcohol-induced AP: When no other etiology was obvious and the patient admitted use of alcohol during the 
week previous to hospitalization, the AP was designated as alcohol-induced.  
 
Biliary AP: When biliary stones were detected in ultrasound examination the AP was designated as biliary. 
 
Idiopathic AP: After diagnosis of AP, possible etiologic factors were assessed (alcohol, biliary stones, 
medication, tumors, hypertriglyceridemia, hypercalcemia). If no such causative factor could be identified, the 




 Severe AP: Severity of AP was categorized by the clinically based classification of the Atlanta symposium 
1993.24 According to this classification, mild AP is associated with minimal organ dysfunction and an 
uneventful recovery. If systemic or local complications or both are present, AP is classified as severe.  
 
OF: OF is consistent with need for mechanical ventilatory support or with hemodialysis due to renal failure. 
Vasopressors were used according to current clinical practice. Criteria for initiating mechanical ventilation 
were tachypnoe with respiratory rate over 35/minute or need for inspiratory oxygen fraction >0.6 in order to 
maintain arterial partial pressure of oxygen  >8 kPa. Hemodialysis was started in patients with significant 
reduction in renal function indicated by increased concentrations of plasma creatinine (>300 mmol/l) or 
plasma urea (>40 mmol/l) and progressive metabolic asidosis (pH<7.28). 
 
Infectious complication: Positive blood culture from wounds, urine or blood during the hospitalization for 
AP. In rare cases, culture samples were taken peroperatively. Fine-needle puncture samples from the intra-
abdominal abscesses and necroses were collected when appropriate.  
 
Laboratory methods 
DNA isolation methods 
 
DNA from the whole blood samples of patients and blood donor controls was extracted with a QIAamp 
DNA isolation kit (Qiagen, Valencia, CA, USA). DNA samples from the WHO/ISBRA Multicenter, 
Multinational Study on the Trait and State Markers of Alcohol Consumption and Alcoholism (218 controls, 




Study I: The mutations were detected by a solid-phase minisequencing using 3H-labeled nucleotides. After 
PCR amplification, 10 µL of the PCR product was captured in streptavidin-coated scintillating microtitration 
plate wells (EG&G Wallac, Turku, Finland) with 40 µL of buffer (0.15 mol/L NaCl, 20 mmol/L Na-
phosphate, pH 7.4, and 0.1% Tween-20) per well. These samples were incubated for 1 hour at room 
temperature with gentle shaking, after which the plate was washed four times with a buffer containing 40 
mmol/L Tris-HCl (pH 8.8), 1 mmol/L EDTA, 50 mmol/L NaCl, and 0.1% Tween-20 with an automatic 




denatured with 100 µL of 50 mmol/L NaOH for 5 minutes at room temperature. The wells were washed four 
times with the washing buffer. 
 
The minisequencing reaction mixture, containing, in separate wells, detection step primers for the N34S (5'-
TTAGGCCAAATGTTACA-3') and P55S (5'-GGACTGATGGAAATACTTAT-3') mutations and wild-type 
alleles at 0.2 µM concentration, the appropriate H dNTPs (Amersham Biosciences Europe, Espoo, Finland) 
at 0.02 µmol/L concentration, and 0.5 U of Dynazyme DNA polymerase in 100 µL of 1× PCR buffer, were 
added to wells. The wells were incubated at 55°C for 15 minutes with gentle shaking and washed four times 
with washing buffer. The incorporated radioactivity was measured in a MicroBeta counter (EG&G Wallac) 
and expressed as counts per minute. The minisequencing reaction was performed in two parallel reactions 
with all four nucleotides for each sample. Results for each sample with a mutation was confirmed by direct 
sequencing by purifying the PCR products using a kit for DNA extraction (Amicon Ultrafree-DA; Millipore 
Corp., Bedford, MA, USA) and sequencing with the ABI Prism Dye Terminator Cycle Sequencing Core Kit 
with AmpliTaq Polymerase and the ABI Prism 310 Genetic Analyser (PE Biosystems, Foster City, CA, 
USA). 
 
Studies II & III: Samples were genotyped by a matrix-assisted laser desorption/ionization time-of flight 
(MALDI-TOF) mass spectrometry-assisted genotyping method (Sequenom, San Diego, CA, USA). TNF 
promoter -308 G/A, CD14 promoter -159 C/T, and HSPA1B +1267 A/G, and IL-10 -592 and -1082 genomic 
sequences were obtained from the SNP consortium database (http://www.ncbi.nlm.nih.gov). PCR assays and 
associated reactions were designated with Spectro DESIGNER software (Sequenom), and primers came 
from Metabion (Planegg-Martinsried, Germany) (Table 5).  
 
All amplification reactions were run in a total volume of 5 µl with 2.5 ng of genomic DNA, 1 pmol of each 
amplification primer, 0.2 mM of each dNTP, 2.5 mM MgCl2, and 0.2 U of HotStarTaq DNA polymerase 
. Extension reactions were conducted in a 
volume of 2 µl, using 5 pmol of allele-specific extension primer and the Mass EXTEND Reagents Kit, 
before being cleaned with SpectroCLEANER (Sequenom) on a MULTIMEK 96 robot (Beckman Coulter, 
Fullerton, CA, USA). Cleaned products were loaded onto a 384-element chip with a nanoliter pipetting 
system. (SpectroCHIP, SpectroJet, Sequenom), analyzed by a MassARRAY mass spectrometer (Sequenom 






Table 5. Database single nucleotide polymorphism identity numbers (DbSNP) and primers used for MALDI-TOF 
determination of polymorphisms. 
 
Gene, SNP DbSNP  
 
5' capture primer  
 
3' capture primer  Extend primer  (5'->3') 





























ELISA measurements of adipokines 
 
Study IV: ELISA (Enzyme-Linked ImmunoSorbant Assay) -based methods, Quantikine Human 
Adiponectin, and Quantikine Human Leptin Immunoassays (R&D Systems, Minneapolis, MN, USA), were 
used to measure adipokine levels. The ACD plasma samples, stored at -80°C, were diluted 100-fold, as 







Statistical significance between the groups was tested with the X2 Chi squared test and Fisher´s exact or 
alternatively the Mann-Whitney U-test when appropriate. P<0.05 was considered statistically significant. 
 
In pretest power analysis for the mutations studied, the prevalence of a mutation of SPINK1 was assumed to 
be 2% in the population and 7% among the patients. The estimate of frequency in the control population was 
based on previous studies, and the frequency in patients was estimated to be one-half of the frequency of the 
mutations found in patients with CP. A sample size of 360 individuals in each group was estimated to be 
sufficient to produce statistically (power 90%, significance 0.05) significant results. 251 
 
The power analysis for sample sizes in populations with unknown genotype frequencies is complicated. 252 
When considering the allele frequencies, a sample size of 360 differences that are smaller than 10% between 
study groups will not be considered statistically significant.  
 
3.3 Results 
SPINK1 mutations (Study I) 
 
The exonic SPINK1 gene mutation N34S occurred in 29 (7.8%) patients with AP and in 12 (2.6%) controls 
(p<0.001, Fisher´s exact test). The P55S mutation was found at a frequency of 0.8% among patients with AP 
and 1.3% among the controls. None of the patients or controls was found to carry both the N43S and P55S 
mutations. The median age of patients with the N34S mutation was 45 years (range 20-73) and was 49 years 
(range 20-94) in those without mutations (p=0.24, Mann-Whitney U-test). One patient, a 28-year-old male 
with idiopathic mild AP, but none of the controls was found to be homozygous for the N34S mutation  
 
Inflammatory gene polymorphisms (Study II) 
 
The allele frequencies of the TNF, HSPA1B, CD14 and IL10 polymorphisms did not differ significantly 
between AP patients and controls (Table 6). These results were in Hardy-Weinberg equilibrium (HWE), with 
the exception of the CD14 gene in the control group of 218 samples from the WHO/ISBRA Multicenter, 




genotyping was repeated for the CD14 locus for all patients and controls, and the results were identical with 
the initial genotyping. 
 
Infectious complications occurred in 47 patients, and these had a genotype distribution not differing from 
that of those with mild, uncomplicated disease. The genotype distribution did not differ significantly between 
patients with alcohol-induced AP and the control group of heavy drinkers. Furthermore, in the patients with 
biliary AP and alcohol-induced AP the major allele frequency was similar.  
 
Haplotypes of the IL-10 promoter were identified as described by Warle.253 As perfect linkage disequilibrium 
exists with IL-10 -592 and IL-10 -  
haplotype is AT, based on genotyping results of locuses IL-10 -1082 and IL-10 -592. We could identify 70 
among those with mild (50; 21% patients) and severe AP (20; 20% patients). Similarly, the patients with 
(13; 5%) and severe (5; 5%) AP.  
 
Hemostatic gene polymorphisms (Study III) 
 
No deviation from HWE could be detected in the genotyping results for FV Leiden and of PAI-1 4G/5G 
genotypes. 
 
The genotype distribution in PAI-1 4G/5G polymorphism between mild and severe AP differed. The 
prothrombotic allele 4G was underrepresented in patients with severe AP, p<0.05. Among those 55 AP 
patients with OF, the allele frequency for 4G was 0.49; 21 patients were homozygotes, and 30 heterozygotes 
for 4G allele in patients with OF. Of 47 patients with infectious complications, homozygotes for the 4G 
mutation were 11 (23.4%) and heterozygotes 28 (59.6%); with an equal allele frequency of 0.53 for 4G in 
this patient group. 
 
The patients with the 4G/4G genotype had a shorter hospital stay than did those carrying the 5G/5G genotype 
(p<0.02, Mann-Whitney U-test). Patients who were homozygote carriers for 4G had hospital a stay median 6 
days (range 1 155), and patients who were homozygote carriers for 5G had median a hospital stay of 10 days 
(range 1 105). Among those with mild AP, a similar trend was evident (p<0.09, Mann-Whitney U-test). The 




(range 1-24). The length of hospital stay was a median 5 (range 1-24) days for those with mild AP and for 
patients with severe AP without OF it was 12.5 (range 1-110) days, significantly longer (p<0.0001, 
MannWhitney U-test). For those with OF the median hospital stay was 43 (range 2-172) days, significantly 
longer than those with severe AP without OF (p<0.0001, Mann-Whitney U-test). The allele frequency for 4G 
was 0.54 among those with alcohol-induced AP and 0.46 for those with biliary AP (p>0.05). 
 
The genotype distribution in the FV Leiden mutation did not differ significantly between mild and severe 
AP. Furthermore, the genotype distributions of the subgroup of the patients with OF and patients with 
infectious complications did not differ from those of patients with mild AP. Of the 47 patients with 
infectious complications, one (2.1%) was detected to be a carrier of the Leiden mutation. The Leiden 
mutaton was detected in six (2.8%) patients with alcohol-induced AP and in two (2.5%) of biliary AP 
patients. Carriership of the Leiden mutation did not affect length of hospital stay. Patients carrying the 
Leiden mutation had a median hospital stay of 8 days (range 5-79), and patients without it had a median 
hospital stay of 7 days (range 1-172), (p>0.05, Mann-Whitney U-test) 
 
Concordant occurrence of prothrombotic polymorphisms, Leiden mutation, and PAI-1 4G was found in ten 
cases of AP. Four patients were among those with mild AP and six among those with severe AP, two of 
whom had infectious complications, and one had OF. 
 
Adipokine levels (Study IV) 
 
The on-admission adiponectin values were a median 5 642 ng/mL (range 1 201-19 400 ng/mL) for the severe 
AP group and median 6 314 ng/mL (range 1 980-24 340 ng/mL) for the mild AP group (p>0.05). The values 
of the nine patients verified to have pancreatic necrosis were a median 5 495 ng/mL (range 1 201-18 822 
ng/mL). Their adiponectin levels remained stable during follow-up in patients with mild AP (Figure 2), but 
in patients with severe AP seemed to vary. Maximum variation in adiponectin level (the highest value minus 
the lowest value) was greater in severe AP (2 456 ng/mL; range 1 270-8 617 ng/mL) than in mild AP, 546 
ng/mL (range 0-2 730 ng/mL), (p=0.001).  
 
 































































































   
































































































































































































































































































































































































































































































































































































The leptin values on admission were median 6.1 ng/mL (range 1.6-72.9 ng/mL) in the severe AP group and 
median 9.0 ng/mL (range 2.5-36.5 ng/mL) in the mild AP group (p>0.05). The peak values (median) were 
12.6 ng/mL (range 2.1-72.9 ng/mL) for severe AP and 10.6 ng/mL (range, 2.7-36.3 ng/mL) for mild AP 
(p>0.05). The nine patients who were verified to have pancreatic necrosis had on-admission leptin levels 
(median) of 6.0 ng/mL (range 1.6-72.9 ng/mL). In the mild AP group (Figure 2), the on-admission value was 
significantly higher than the respective 2 to 4 days' value (p=0.005). In the severe AP group, the values on 







The aim of a genetic study is to identify heritable disease-related genotypes, mutations, phenotypes, or 
karyotypes. Twin studies and family studies with linkage analysis are powerful study settings for genetic 
studies. In AP the case-control setting with association analysis is available due to the complex nature of the 
disease. 
 
The relative risk of a genotype affects sample-size requirements. Furthermore, disease allele frequency 
affects minimum sample size requirements. Higher allele frequency is associated with larger sample size 
requirements in order to reveal statistical associations.254 In AP, the relative risk of any genotype is likely to 
be modest, and sample group size requirements are higher than the sizes available. Our study population is 
relatively large compared to other patient samples reported thus far. However, because we study a 
multifactorial disease, the patient population should be over 1000. As our main interest is severe AP and 
possibly more particularly OF accompanying severe AP, our patient sample can be considered modest. 
 
Here we present the results of the thus-far largest case-control association study of AP and inflammatory 
gene polymorphisms.  The study involved 397 patients, of whom 154 had severe AP, and of those, 55 
patients had OF, the feature closely associated with mortality from AP. Our retrospectively collected patient 
group is subject to some problems concerning the most seriously affected individuals, not included because 
they were dead or disabled, unable to participate in voluntary blood sampling. However, the retrospective 
group included only patients with severe AP according to the criteria of Atlanta, and as high as 40% of them 





A case-control study setting is sensitive to multiple confounding factors like population stratification.255 In 
our study, the control populations were drawn from the Metropolitan Helsinki Area (Uusimaa), the same area 
from which patients are allocated to the Helsinki University Hospital, as we aimed at minimizing population 
stratification. Furthermore, all the study subjects were Caucasian. The Finnish WHO/ISBRA study subjects 
represented a group with clearly defined alcohol consumption and no pancreatic disease. As to blood donors, 
it was unknown whether they had pancreatitis, and furthermore, their lifestyle may have been protective 
against AP compared to that of the general population. 
 
We had the opportunity to focus on alcohol-induced AP because its incidence in Finland is extremely high. 
Due to this incidence, in this population the identification of genetic factors may indeed be possible. It is also 
possible that the Finns´ high incidence of alcoholic pancreatitis is related more to their binge-drinking pattern 
and to diet. However, if such a genetic factor exists, Finns are a good population in which to study it. In the 
metropolitan area of Helsinki, Uusimaa, the population is not as isolated as in remote provinces and Lapland. 
Those population isolates would be even more ideal for studying complex traits.256 
 
The subgroup defined as heavy drinkers consumed alcohol at more than 40 g/day. This amount of alcohol, by 
definition, is not high. Ideally, the control group would have been people consuming even higher amounts of 
alcohol and being examined for pancreatic disease. Selection of a well-matched control group is of high 
importance in genetic case-control studies. 257 
 
Misclassification errors are possible in genotypes and in phenotypes and cause loss of study power. We 
dissected the trait components of severe AP: OF and infectious complications. Furthermore, we identified the 
alcoholic etiology. The definition of alcoholic AP could have been made more strictly by employing 
disialotransferrin measurements or formulating inquiries into alcohol consumption. We do not know whether 
our definitions of trait components are optimal, and the researcher has to be open to new ideas of dissecting 
complex traits.258, 259 
 
As to our genotyping procedure, our results can be considered reliable. Only a small number of samples 
(1.1%) were not genotyped. We repeated the genotyping of CD14 polymorphism, and no misclassifications 
were detectable. For case-control data, duplicate samples can be genotyped, and controls are tested for 
deviations from HWE. Duplicate samples can provide accurate estimates of genotyping error rates, unless 
systematic genotyping errors have occurred. Although genotyping errors can cause deviations from HWE, 
these deviations are usually small, and the power to detect them is low except for high rates of genotyping 





The matched case-control design in Study IV provides an efficient method of controlling for major 
confounders.  
 
Statistical methods were adopted according to the principal rules. The chi squared X2 test and Fisher´s exact 




This is, to our knowledge, the first report of SPINK1 gene mutations in AP and shows a surprisingly high 
prevalence (7.8%) of the N34S mutation of the SPINK1 gene in 371 patients. Our finding suggests a link 
between SPINK1 mutations and AP: The SPINK1 N34S mutation was associated not only with a particular 
type of CP but may also be a risk factor for pancreatitis in general. The frequency of the N34S mutation in 
the control population of 2.6% is comparable with that in other studies. No association emerged between the 
other SPINK1 mutation, P55S, and AP. A trend did emerge for the N34S mutation to be more common in 
patients with severe AP (9.1%). This, however, failed to reach statistical significance, and further study is 
warranted before considering the N34S mutation as a risk factor for severe AP. In summary, in this study, as 
many as 7.8% of patients with AP were carriers of the SPINK1 N34S mutation. This suggests that the 




Contrary to previous findings, we can demonstrate no differences between our study groups of mild and 
severe AP and controls. Furthermore, the group of patients with OF and similarly the group of severe-AP 
patients with infectious complications did not show different genotypes from those of controls. Thus, 
determination of these polymorphisms may be of no value in predicting disease severity in AP.  
 
Several case-control studies present associations of AP with TNF -308 G/A polymorphism. TNF -308 G/A 
polymorphism has been associated with early septic shock and with severe AP (Table 2). Our data on 214 
AP patients with alcohol-induced disease adds a considerable amount of evidence that TNF -308 G/A 




thus be assumed that this negative finding between risk and severity is valid also for other etiologies such as 
biliary and idiopathic AP, contrary to some earlier findings.  
 
Our results are not in accordance with the association of HSPA1B +1267 polymorphism with severity of AP 
as presented by Balog and colleagues. This is not surprising, because conflict among sequential studies is a 
common phenomenon in case-control studies.261, 262, 263 Classification of severe AP followed different rules in 
the present study (Atlanta classification) and in the study of Balog and colleagues. (Ranson classification). 
Locus heterogeneity offers one explanation; we, however, did a subgroup analysis of different etiologies and 
found no differences between groups.  
 
The most likely explanation for the association sometimes demonstrated in AP in the genes HSPA1B and 
TNF -308 is that haplotypes neighboring these SNPs are causative for the phenotype. Both these genes are 
located in chromosome 6, near the MHC genes. Indeed, in alcoholic CP, association with TNF microsatellite 
haplotypes may occur.264 HSPA1B intronic +1267 polymorphism does not alter the structure of the protein, 
and may be a marker of haplotypes associated with multiple diseases.265, 266, 267, 268 The positive associations 
found in other diseases encourage us to go further with studying HSPA1B gene haplotypes.269, 270 Other 
haplotypes of the TNF gene may be important, as demonstrated in other diseases. 271, 272, 273 
 
Now we have very strong evidence that CD14 -159 C/T polymorphism is not associated with disease 
outcome in AP. 20,198,200,201 None of these studies suggests that CD14 -159 C/T polymorphism is associated 
with AP or complications. Chao and colleagues report from Taiwan that the CD14 -159 C allele is associated 
with alcoholic AP.24 In our patient sample, we could not confirm this finding. The patient population in the 
Chao study consumed high amounts of alcohol: a reported 140 g/day for 15 years. The amount of alcohol 
consumed is also high in reports associating the T allele with liver cirrhosis. We were unable to record the 
amount of alcohol consumed by our patients, so we only assume that their alcohol consumption exceeded 80 
g/day, and quite often AP is associated with a binge-drinking pattern. Thus, our results do not rule out the 
possibility that CD14 -159 C/T polymorphism can play a role in organ damage in long-lasting exposure to 
alcohol. 
 
Based on our results, the FV Leiden mutation does not affect AP severity. Carriers of the Leiden mutation 
were evenly distributed among those with mild AP, severe AP, and severe AP with infectious complications 
or OF. The allele frequency for the Leiden mutation in this study was 2% both in patients and in controls, 





Our finding is the underexpression of the PAI-1 G4 allele among those with severe AP (p<0.05). 
Furthermore, the median hospital stay was shorter among those with the 4G/4G genotype. This finding is 
very contrary to our hypothesis. The PAI-1 4G allele is associated with higher PAI-1 levels and favors 
coagulation. High PAI-1 levels in AP have been associated with mortality.276 The 4G/4G homozygosity has 
been associated with obesity, a risk factor for severe AP.277 All in, it can be concluded that the PAI-1 4G/5G 




Our results suggest that adiponectin and leptin plasma concentrations on admission are not involved as 
determinants of disease severity in AP, because plasma concentrations of adiponectin and leptin were similar 
in the groups of patients with mild and with severe AP. In AP patients matched by age, gender, BMI, and 
etiology, the on-admission plasma levels of adiponectin and leptin did not correlate with disease severity, 




The results of the present study show that there are, indeed, genetic factors involved in AP.  Further 
identification of genetic factors in a multifactorial disease such as AP is becoming possible with employment 
of modern techniques in genetics. This requires clearly defined patient populations in regards also to the 
acquired risk factors in AP and even larger AP patient sample sizes with multicenter collaboration in patient 
collection. Employment of new technologies in genotyping enables the investigator to identify vast numbers 
of genetic variants. Analysis of the data requires advanced analytical and statistical methods that are 
available.  
 
Further clarification of the complex trait of severe AP may be possible in clinical studies. Risk factors 
identified thus far are advanced age, comorbidities, and obesity. Features of the metabolic syndrome serve as 
a tempting starting point for study to identify additional factors associated with severity of AP. Detailed 
knowledge of clinical factors associated with the severity of AP aids in interpretation of future genetic 









Results of the present study suggest that: 
 
 
1. The SPINK1 N34S mutation is a predictive factor in AP. This mutation appeared in 7.8% of our AP 
patients compared with 2.6% of controls, indicating that it is a risk factor for AP. The SPINK1 N55S 
mutation showed no differences between study groups.  
 
2. Inflammatory gene polymorphisms in genes CD14, TNF, IL-10, and HSPA1B have no influence on 
AP, since the polymorphisms showed no associations with severe AP or alcohol-induced AP 
compared with controls.  
 
3. FV Leiden and PAI-1 4G/4G are not risk factors in severe AP because OF or infectious complications 
in severe AP were not more common in patients carrying these genotypes. 
 
4. Plasma adipokines have no influence on systemic inflammation in clinical AP, since adiponectin and 




The identification of genetic factors associated with severe AP requires large patient populations with 
precisely characterized clinical risk factors, as well as familiarity with the pathogenesis of the disease. AP 
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